Contact Us
Attn: Ann Sun
Tel: +86-532-81926227
Fax: +86-532-81926219
Industry Trends

Location:Home > News Room > Industry Trends >

China's new Alzheimer's drug completes phase 3 clinical trial

Posted by:bozhihuili    Published:2018-07-18 10:10

SHANGHAI - A Chinese research group on Tuesday announced progress in developing a drug to 

treat Alzheimer's disease.

GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medica under 

Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after a 21-year study.

A phase three clinical trial is the last test before reaching the market.

In the trial, participants took 450 mg GV-971 orally twice a day for 36 weeks, which proved effective 

in improving cognition.

Extracted from brown algae, the drug is targeted at patients with mild-to-moderate Alzheimer's. 

Independent animal experiments also showed that it can regulate the immune system, reduce 

neuro-inflammation and improve cognition.

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory, 

thinking skills, and the ability to carry out simple tasks. The disease affects about 48 million 

people worldwide, and the number is expected to increase with the aging population. There 

is no effective cure.

The drug opens a new avenue for treatment and provides patients with a new solution and hope, 

said lead researcher Geng Meiyu.

From: Chinadaily news  July 17th, 2018

BZ Oligo is a profesional manufacturer of alginate oligsoaccharides, which including M block (sodium 

oligo-mannuronate), G block (sodium oligo-guluronate) and M & G mixture. For more information, 

kindly click following link:

Alginate Oligosaccharide Ingredients:

Alginate Oligosaccharide Standarded Substances (Monomer~Decamer):

Copyright©Qingdao BZ Oligo Biotech Co., Ltd  Tel:0532-81926227  Fax:0532-81926219  DesDev Inc.
Headquarter:Room 806, D&D Fortune Center, No. 182-6 Haier Road, Qingdao 266061, China